Topic Hub
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 8 of 8 clinical reviews.
A prescriber-level guide to recognizing, grading, and managing adverse events with siRNA lipid therapeutics, inclisiran, fitusiran, and related agents, covering injection-site reactions, liver effects, bleeding risk, and off-target monitoring.
Read clinical reviewA complete MD/PharmD-level guide to the siRNA lipid therapeutics drug class, inclisiran prescribing, billing codes, and prior authorization strategies for twice-yearly LDL reduction.
Read clinical reviewA prescriber-level DDI reference for siRNA lipid therapeutics (inclisiran, vutrisiran, patisiran). Covers mechanism, pharmacokinetics, DDI table, dosing, and monitoring guidance with primary literature citations.
Read clinical reviewA physician- and pharmacist-level guide to the siRNA lipid therapeutics drug class, focusing on inclisiran's monitoring bundle, dosing schedule, safety labs, and prescribing requirements per current ACC/AHA and FDA guidance.
Read clinical reviewA clinical guide to siRNA lipid therapeutics, inclisiran dosing schedules, titration logic, tapering considerations, and prescribing decisions for cardiologists and primary care providers.
Read clinical reviewA prescriber- and pharmacist-level monograph on the siRNA lipid therapeutics drug class, covering mechanism, pharmacokinetics, clinical trial data, dosing, safety, and place in therapy for LDL-C reduction.
Read clinical reviewA prescriber-level guide to siRNA lipid-lowering agents, covering inclisiran pharmacology, patient selection, dosing, and how to choose between available agents based on current trial data and guidelines.
Read clinical reviewClinician-focused review of siRNA lipid therapeutics (inclisiran) across special populations including renal impairment, hepatic impairment, elderly patients, and pregnancy. Dosing adjustments, monitoring, and evidence gaps.
Read clinical review